Company Description
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.
The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014.
ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Country | United States |
IPO Date | n/a |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | John B. Payne |
Contact Details
Address: 21 East Long Lake Road Bloomfield Hills, Michigan United States | |
Website | https://www.zivobioscience.com |
Stock Details
Ticker Symbol | ZIVOW |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001101026 |
CUSIP Number | n/a |
ISIN Number | US98978N2009 |
Employer ID | 87-0699977 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
John B. Payne | President, Chief Executive Officer & Chairman of the Board |
Keith R. Marchiando | Chief Financial Officer, Treasurer & Secretary |
Dr. Harlan L. Miller III | Vice President of Technology & Global Supply |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 15, 2024 | 8-K | Current Report |
Nov 14, 2024 | 10-Q | Quarterly Report |
Oct 18, 2024 | 8-K | Current Report |
Oct 17, 2024 | 4 | Filing |
Oct 16, 2024 | 4 | Filing |
Oct 01, 2024 | 3 | Filing |
Oct 01, 2024 | SC 13D/A | [Amend] Filing |
Aug 23, 2024 | 4 | Filing |
Aug 23, 2024 | 4 | Filing |
Aug 14, 2024 | 10-Q | Quarterly Report |